AstraZeneca (AZN) Selects Regulus Therapeutics (RGLS) RG-125 for NASH Treatment in Patients with Type 2 Diabetes
Tweet Send to a Friend
Regulus Therapeutics (NASDAQ: RGLS) announced the selection of RG-125 (AZD4076), a GalNAc-conjugated anti-miR targeting microRNA-103/107 ("miR-103/107") for the treatment of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE